ARQT Relative Valuation
ARQT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ARQT is overvalued; if below, it's undervalued.
Historical Valuation
Arcutis Biotherapeutics Inc (ARQT) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -8.77. The fair price of Arcutis Biotherapeutics Inc (ARQT) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：31.16
Fair
82.22
PE
1Y
3Y
5Y
Trailing
Forward
37.41
EV/EBITDA
Arcutis Biotherapeutics Inc. (ARQT) has a current EV/EBITDA of 37.41. The 5-year average EV/EBITDA is -11.49. The thresholds are as follows: Strongly Undervalued below -80.82, Undervalued between -80.82 and -46.16, Fairly Valued between 23.17 and -46.16, Overvalued between 23.17 and 57.83, and Strongly Overvalued above 57.83. The current Forward EV/EBITDA of 37.41 falls within the Overvalued range.
67.52
EV/EBIT
Arcutis Biotherapeutics Inc. (ARQT) has a current EV/EBIT of 67.52. The 5-year average EV/EBIT is -12.64. The thresholds are as follows: Strongly Undervalued below -97.12, Undervalued between -97.12 and -54.88, Fairly Valued between 29.60 and -54.88, Overvalued between 29.60 and 71.84, and Strongly Overvalued above 71.84. The current Forward EV/EBIT of 67.52 falls within the Overvalued range.
8.35
PS
Arcutis Biotherapeutics Inc. (ARQT) has a current PS of 8.35. The 5-year average PS is 102.10. The thresholds are as follows: Strongly Undervalued below -253.12, Undervalued between -253.12 and -75.51, Fairly Valued between 279.71 and -75.51, Overvalued between 279.71 and 457.32, and Strongly Overvalued above 457.32. The current Forward PS of 8.35 falls within the Historic Trend Line -Fairly Valued range.
73.69
P/OCF
Arcutis Biotherapeutics Inc. (ARQT) has a current P/OCF of 73.69. The 5-year average P/OCF is -2.33. The thresholds are as follows: Strongly Undervalued below -48.28, Undervalued between -48.28 and -25.31, Fairly Valued between 20.65 and -25.31, Overvalued between 20.65 and 43.63, and Strongly Overvalued above 43.63. The current Forward P/OCF of 73.69 falls within the Strongly Overvalued range.
49.59
P/FCF
Arcutis Biotherapeutics Inc. (ARQT) has a current P/FCF of 49.59. The 5-year average P/FCF is 6.63. The thresholds are as follows: Strongly Undervalued below -62.97, Undervalued between -62.97 and -28.17, Fairly Valued between 41.43 and -28.17, Overvalued between 41.43 and 76.23, and Strongly Overvalued above 76.23. The current Forward P/FCF of 49.59 falls within the Overvalued range.
Arcutis Biotherapeutics Inc (ARQT) has a current Price-to-Book (P/B) ratio of 23.71. Compared to its 3-year average P/B ratio of 7.99 , the current P/B ratio is approximately 196.82% higher. Relative to its 5-year average P/B ratio of 6.34, the current P/B ratio is about 273.72% higher. Arcutis Biotherapeutics Inc (ARQT) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -30.63%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -24.33% , the current FCF yield is about -100.00% lower.
23.71
P/B
Median3y
7.99
Median5y
6.34
-0.91
FCF Yield
Median3y
-30.63
Median5y
-24.33
Competitors Valuation Multiple
The average P/S ratio for ARQT's competitors is 0.00, providing a benchmark for relative valuation. Arcutis Biotherapeutics Inc Corp (ARQT) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 121.69%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ARQT increased by 123.69% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 44.76M to 99.22M.
The secondary factor is the P/E Change, contributed 110.05%to the performance.
Overall, the performance of ARQT in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Arcutis Biotherapeutics Inc (ARQT) currently overvalued or undervalued?
What is Arcutis Biotherapeutics Inc (ARQT) fair value?
How does ARQT's valuation metrics compare to the industry average?
What is the current P/B ratio for Arcutis Biotherapeutics Inc (ARQT) as of Dec 05 2025?
What is the current FCF Yield for Arcutis Biotherapeutics Inc (ARQT) as of Dec 05 2025?
What is the current Forward P/E ratio for Arcutis Biotherapeutics Inc (ARQT) as of Dec 05 2025?